Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways

12 Oct 2016

Abstract excerpt

BACKGROUND: Malignant gliomas are associated with a high mortality rate, and effective treatment options are limited. Thus, the development of novel targeted treatments to battle this deadly disease is imperative. METHODS: In this study, we investigated the in vitro effects of the novel reversible chromosomal region maintenance 1 (CRM1) inhibitor S109 on cell proliferation in human gliomas. S109 was also...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Glioma Diagnosis and Treatment
Share to Nuclear Structure and Function

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27733172
DOI: 10.1186/s13045-016-0338-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathwaysPMID 27733172Read ↗

Inhibition of chromosomal region maintenance 1 suppresses the migration and invasion of glioma cells via inactivation of the STAT3/MMP2 signaling pathwaySemantic proximity Read ↗

Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its InhibitorSemantic proximity Read ↗

The past, present, and future of CRM1/XPO1 inhibitorsSemantic proximity Read ↗

EXPRESSION OF CRM1 IN HUMAN GLIOMAS AND ITS SIGNIFICANCE IN P27 EXPRESSION AND CLINICAL PROGNOSISSemantic proximity Read ↗

CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1–Dependent IGF-1 SignalingSemantic proximity Read ↗

Inhibiting cancer cell hallmark features through nuclear export inhibitionSemantic proximity Read ↗

XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexorSemantic proximity Read ↗

Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.Semantic proximity Read ↗

ANTXR1 Facilitates Tumor Growth in Glioma via Deactivating MAPK Signaling PathwaySemantic proximity Read ↗

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.Semantic proximity Read ↗

GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAFV600E Colorectal CancerSemantic proximity Read ↗

Musashi-1 regulates cell cycle and confers resistance to cisplatin treatment in Group 3/4 medulloblastomas cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.